Search

everythinglearnresearchcommunity

for

Search:↓

Some breast cancer chemotherapy can cause permanent hair loss.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Hair and nail changes can indicate health issues, including cancer and side effects from cancer treatments.

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.

Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.

Scalp cooling is largely ineffective in preventing hair loss from breast cancer chemotherapy.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.

Curcumin may be an effective and safer anticancer agent by regulating key cell pathways.

X-ray diffraction of hair might help detect breast cancer non-invasively.

The conclusion is that there might be a link between certain types of baldness and prostate cancer, which could be due to shared hormonal pathways.

Liposomes show promise in cancer treatment by delivering drugs with less toxicity and improved effectiveness.

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Puerto Rican children with cancer often experience symptoms like irritability, nausea, and hair loss, and need better education and continuous symptom management.

No definitive link between finasteride and male breast cancer, but further research is needed.

Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.

Madarosis (eyebrow and eyelash loss) significantly affects quality of life for breast cancer patients on taxane-based chemotherapy.

Chemotherapy causes hair loss in cancer patients by affecting both growing and resting hair.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.